These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Von Willebrand factor in the outcome of temporal arteritis. Cid MC; Monteagudo J; Oristrell J; Vilaseca J; Pallarés L; Cervera R; Font C; Font J; Ingelmo M; Urbano-Márquez A Ann Rheum Dis; 1996 Dec; 55(12):927-30. PubMed ID: 9014589 [TBL] [Abstract][Full Text] [Related]
5. [Comparative study of von Willebrand factor in patients with temporal arteritis]. González-Gay MA; Alvarez MD; Machín AJ; Alonso MD; García González J; Cereijo MJ; Bal M An Med Interna; 1992 Oct; 9(10):483-6. PubMed ID: 1420759 [TBL] [Abstract][Full Text] [Related]
6. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Blann AD; Dobrotova M; Kubisz P; McCollum CN Thromb Haemost; 1995 Aug; 74(2):626-30. PubMed ID: 8584997 [TBL] [Abstract][Full Text] [Related]
7. Endothelial cell markers (vWF, t-PA and PAI-1) in the elderly. Gaussem P; Levy C; Verny M; Anglés-Cano E Thromb Haemost; 1994 Jul; 72(1):164-5. PubMed ID: 7974369 [No Abstract] [Full Text] [Related]
8. Von Willebrand factor in polymyalgia rheumatica and giant cell arteritis. Uddhammar AC Clin Exp Rheumatol; 2000; 18(4 Suppl 20):S32-3. PubMed ID: 10948757 [TBL] [Abstract][Full Text] [Related]
9. The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial. Rautio A; Boman K; Gerstein HC; Hernestål-Boman J; Lee SF; Olofsson M; Mellbin LG Diab Vasc Dis Res; 2017 Jul; 14(4):345-352. PubMed ID: 28403644 [TBL] [Abstract][Full Text] [Related]
10. Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction. Andreotti F; Hackett DR; Haider AW; Roncaglioni MC; Davies GJ; Beacham JL; Kluft C; Maseri A Thromb Haemost; 1992 Dec; 68(6):678-82. PubMed ID: 1287882 [TBL] [Abstract][Full Text] [Related]
11. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism. Levesque H; Borg JY; Cailleux N; Vasse M; Daliphard S; Gancel A; Monconduit M; Courtois H Eur J Med; 1993 May; 2(5):287-8. PubMed ID: 8252160 [TBL] [Abstract][Full Text] [Related]
12. [Assessment of plasminogen activator inhibitor-1 and von Willebrand factor as a markers of endothelial function in patients with end-stage kidney disease after allotransplantation during a one-year follow-up]. Doroszewski W; Włodarczyk Z; Strózecki P; Manitius J; Grabarczyk E; Rość D; Odrowaz-Sypniewska G Pol Arch Med Wewn; 2007; 117(5-6):213-20. PubMed ID: 18030870 [TBL] [Abstract][Full Text] [Related]
13. Serological and immunohistochemical determination of von Willebrand factor antigen in serum and biopsy specimens from patients with arteritis temporalis and polymyalgia rheumatica. Olsson A; Elling P; Elling H Clin Exp Rheumatol; 1990; 8(1):55-8. PubMed ID: 2189625 [TBL] [Abstract][Full Text] [Related]
14. von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator. Schved JF; Gris JC; Arnaud A; Martinez P; Sanchez N; Wautier JL; Sarlat C J Lab Clin Med; 1992 Sep; 120(3):411-9. PubMed ID: 1517688 [TBL] [Abstract][Full Text] [Related]
15. Altered endothelial function following the Fontan procedure. Binotto MA; Maeda NY; Lopes AA Cardiol Young; 2008 Feb; 18(1):70-4. PubMed ID: 18093358 [TBL] [Abstract][Full Text] [Related]
16. Endothelial haemostatic factors may be associated with mortality in patients on long-term anticoagulant treatment. Brännström M; Jansson JH; Boman K; Nilsson TK Thromb Haemost; 1995 Aug; 74(2):612-5. PubMed ID: 8584993 [TBL] [Abstract][Full Text] [Related]
17. Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy. Boman K; Boman JH; Andersson J; Olofsson M; Dahlöf B Clin Appl Thromb Hemost; 2010 Apr; 16(2):146-52. PubMed ID: 19825910 [TBL] [Abstract][Full Text] [Related]
18. Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators. Zareba W; Pancio G; Moss AJ; Kalaria VG; Marder VJ; Weiss HJ; Watelet LF; Sparks CE Thromb Haemost; 2001 Sep; 86(3):791-9. PubMed ID: 11583309 [TBL] [Abstract][Full Text] [Related]
19. Type 2 diabetes: assessment of endothelial lesion and fibrinolytic system markers. Soares AL; Sousa Mde O; Dusse LM; Fernandes AP; Lasmar MC; Novelli BA; Lages Gde F; Carvalho Md Blood Coagul Fibrinolysis; 2007 Jul; 18(5):395-9. PubMed ID: 17581312 [TBL] [Abstract][Full Text] [Related]
20. [Rhizomelic pseudopolyarthritis (polymyalgia rheumatica) and the problem of very high sedimentation rates]. Saudan Y; Chavannes F Helv Med Acta Suppl; 1969; 49():191-5. PubMed ID: 5268893 [No Abstract] [Full Text] [Related] [Next] [New Search]